Skip to main content
. 2016 Sep 21;7(46):75328–75338. doi: 10.18632/oncotarget.12175

Figure 4. In vivo evaluation of RG7112 efficacy using xenografted RMG-I cells.

Figure 4

A-C. Tumor size and body weight in xenograft mouse models orally treated with RG7112 were measured after the start of RG7112 treatment 13 days post implantation (A). Tumors were collected from mice sacrificed after 21 days of RG7112 treatment (B). Tumor weights were compared by t-test between control and RG7112-treated animals (C). D. TP53 phosphorylation and expression of TP53 target proteins were compared between tumors from control and RG7112-treated animals (n = 3 per group). E. Expression of each protein relative to beta-actin was quantified in Image J. All experiments were repeated thrice.